Pharming Receives Expanded FDA Approval for Joenja in Younger Patients

Key Facts

1Pharming Group N.V. has received approval for its drug Joenja to be used in a younger age group.

In a move that highlights the growth potential within the rare disease biotech sector, Pharming Group N.V. has secured regulatory approval to expand the indication for its drug Joenja (leniolisib). According to reports, the approval extends the use of the treatment to a younger demographic, specifically children aged 4 to 11. This expansion targets APDS, a rare primary immunodeficiency, significantly broadening the addressable patient population for the company’s key product.

This development reflects the company's strategic focus on maximizing the clinical utility of its existing portfolio. Per market analysis, the expanded approval for Joenja is viewed as a bullish driver for the stock, as it increases the total addressable market. The drug was previously restricted to older age groups, and this regulatory milestone is expected to support revenue growth by addressing an unmet medical need in younger pediatric patients.

In the equity markets, PHAR shares stood at $10.81 at the close of September 10, 2026, having traded between a high of $10.97 and a low of $10.67 during that session. While the upcoming economic calendar shows no direct catalysts for the company in the immediate seven-day window, traders may look to the recent daily low of $10.67 as a potential technical support level following this regulatory news.